Utilizing dual-specific CD4+ T cells in combination with oncolytic virotherapy for treatment of cancer (P2118)

Abstract Engineering T cell specificity to direct them against tumor cells utilizing chimeric antigen receptors (CARs) has emerged as an exciting technique for adoptive T cell therapy. The effectiveness of adoptive transfer therapies can be limited by a number of factors, including ability of T cells to engraft, the degree to which they infiltrate the tumor, and the immunosuppressive nature of the tumor. Oncolytic viruses (OVs) are capable of …